Major bleeding
Major bleeding OR 2.73 (9.24% vs 3.42%) compared to anticoagulant alone
Intracranial hemorrhage OR 4.63 (1.46% vs 0.19%)
There was no statistically significant increase in major bleeding risk in patients 65yo or younger
No standard or evidence-based reversal regimen exists but general guidelines include: 
Supportive care (e.g. transfusion)
Cryoprecipitate (contains fibrinogen) 10 units or more to achieve fibrinogen level >150 mg/dL
TXA or aminocaproic acid are antifibrinolytics, but limited data
PCC or FFP can be considered, but generally as adjuncts to cryoprecipitate
Consider vitamin K
Platelets controversial (theoretical benefit, but a small study showed worsening ICH with platelets)
Consider neurosurgical intervention if large ICH is found on CT
Major bleeding OR 2.73 (9.24% vs 3.42%) compared to anticoagulant alone
Intracranial hemorrhage OR 4.63 (1.46% vs 0.19%)
There was no statistically significant increase in major bleeding risk in patients 65yo or younger
Supportive care (e.g. transfusion)
Cryoprecipitate (contains fibrinogen) 10 units or more to achieve fibrinogen level >150 mg/dL
TXA or aminocaproic acid are antifibrinolytics, but limited data
PCC or FFP can be considered, but generally as adjuncts to cryoprecipitate
Consider vitamin K
Platelets controversial (theoretical benefit, but a small study showed worsening ICH with platelets)
Consider neurosurgical intervention if large ICH is found on CT
Thrombolytics for pulmonary embolism
Thrombolytics for STEMI
Thrombolytics for acute ischemic stroke
Balloon tamponade for massive GI bleeding
Resuscitative endovascular balloon occlusion of the aorta
Anti-platelet agent reversal
Cardiovascular antibiotics
Formal echocardiography